In8Bio (INAB) EPS (Basic) (2020 - 2026)

In8Bio (INAB) posted EPS (Basic) of -$0.26 for Q1 2026, up 76.32% sequentially from -$1.11 in Q4 2025, and up 92.56% YoY from -$0.14 in Q1 2025.

In8Bio (INAB) EPS (Basic) (2020 - 2026) Analysis & Trends

In8Bio has reported EPS (Basic) for 7 years, with the latest figure at -$0.26 in Q1 2026.

Quarterly EPS (Basic) rose 92.56% year-over-year to -$0.26 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.03 (up 95.51% YoY) and the FY2025 annual result came in at -$10.66, up 65.66% from the prior year.
EPS (Basic) climbed to -$0.26 in Q1 2026 per INAB's latest filing, from -$1.11 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.26 in Q1 2026 and troughed at -$27.37 in Q4 2023.
A 5-year average of -$8.83 and a median of -$9.81 in 2022 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2025: EPS (Basic) sank 120.91% in 2023, then jumped 93.68% in 2025.
Over 5 years, EPS (Basic) stood at -$12.39 in 2022, then tumbled by 120.91% to -$27.37 in 2023, then surged by 35.93% to -$17.53 in 2024, then surged by 93.68% to -$1.11 in 2025, then surged by 76.32% to -$0.26 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.26, -$1.11, and -$0.97 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	12.62
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	7.59
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.23
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-0.72
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.18
10	In8Bio	24.34 Mn	24.34 Mn	-	-0.24

Download Data